Ornibel (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Ornibel, is a combined hormonal contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age. GNH USA supplies Ornibel as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ornibel as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ornibel is a combined hormonal contraceptive that acts on the reproductive endocrine pathway to prevent pregnancy.

- Contraception: Provides reliable prevention of ovulation and pregnancy when taken as prescribed. - Menstrual cycle regulation: Helps achieve more predictable menstrual bleeding patterns. - Acne management: Reduces androgen‑related skin lesions in women requiring contraception.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like. - Breast tenderness: temporary swelling or discomfort. - Spotting between periods: light vaginal bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional lability.

Serious or Rare Side Effects: - Venous thromboembolism: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack in susceptible individuals. - Severe allergic reaction: anaphylaxis or angioedema. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Ornibel, consider patient‑specific factors and follow safety guidelines.

- Smoking status: avoid use in women over 35 who smoke regularly. - Cardiovascular risk: assess history of hypertension, thrombosis, or heart disease. - Liver function: evaluate for active liver disease or dysfunction. - Migraine history: caution in patients with migraine with aura. - Medication adherence: ensure consistent daily intake for effectiveness. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and direct sunlight.

Ornibel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antiepileptic enzymes inducers (e.g., carbamazepine, phenytoin): reduce hormonal levels. - Rifampicin: markedly decreases contraceptive effectiveness. - St. John’s wort: herbal inducer that lowers plasma concentrations.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone exposure. - Antibiotics (e.g., clarithromycin): potential modest reduction in efficacy. - Antidepressants (SSRIs): possible increased risk of mood‑related side effects.